NanoGenics

Nanogenics is a UK research based virtual biotechnology company. Founded to develop the LipTide™ nanoformulation platform, the focus now is on developing product ECP105 through preclinical and towards clinical testing. ECP105 is under development for the treatment of Glaucoma patients undergoing trabeculectomy surgery. This surgical technique relieves intra-ocular pressure by creating a channel into which the eye drains. Although well established and successful, surgical failure can occur if the surgical wound undergoes fibrosis and the scar prevents drainage. The active ingredient of ECP105 is an siRNA designed to down-regulate a gene involved in scarring and fibrosis. Using a single sub-conjunctival injection of ECP105 during trabeculectomy surgery the risk of scarring will be lowered leading to improved surgical outcomes and reduced need for repeat surgery. Presented in the LipTide™ formulation, ECP105 targets the relevant cells of the eye in a safe and predictable manner. LipTideᵀᴹ is a peptide nanoparticle that has already shown excellent in vivo efficacy across a range of models and delivery routes, including nebulised and systemic administration. This targeted, receptor-mediated, active uptake means that LipTideᵀᴹ can be used to deliver any type of nucleic acid payload, including gene editing tools and nucleic acid vaccines. LipTide™ is available as a platform to encapsulate DNA and RNA with the patented lipid/peptide formulation. Nanogenics is interested in meeting potential clinical investment partners to discuss licencing opportunities for LipTideᵀᴹ. Contacts: Suzy Dilly [email protected]